Abstract
When early prophase PtK1 or Indian muntjac cells are exposed to topoisomerase II (topo II) inhibitors that induce little if any DNA damage, they are delayed from entering mitosis. We show that this delay is overridden by inhibiting the p38, but not the ATM, kinase. Treating early prophase cells with hyperosmotic medium or a histone deacetylase inhibitor similarly delays entry into mitosis, and this delay can also be prevented by inhibiting p38. Together, these results reveal that agents or stresses that induce global changes in chromatin topology during G2 delay entry into mitosis, independent of the ATM-mediated DNA damage checkpoint, by activating the p38 MAPK checkpoint. The presence of this pathway obviates the necessity of postulating the existence of multiple “chromatin modification” checkpoints during G2. Lastly, cells that enter mitosis in the presence of topo II inhibitors form metaphase spindles that are delayed in entering anaphase via the spindle assembly, and not the p38, checkpoint.
References
57
Referenced
112
10.1038/nature01368
/ Nature. (2003)10.1073/pnas.251194298
/ Proc. Natl. Acad. Sci. USA. (2001)10.1101/gad.1107303
/ Genes Dev. (2003)10.1038/35075107
/ Nature. (2001)10.1016/S0959-437X(01)00270-2
/ Curr. Opin. Genet. Dev. (2002)10.1098/rspb.1951.0041
/ Proc. R. Soc. Lond. B. Biol. Sci. (1951)10.1016/S0161-5890(02)00262-6
/ Mol. Immunol. (2003)10.1016/S0306-4522(02)00096-9
/ Neuroscience. (2002)10.1016/S0960-9822(02)00673-5
/ Curr. Biol. (2002){'key': '2023072218191873900_BIB10', 'first-page': '1797', 'volume': '62', 'year': '2002', 'journal-title': 'Cancer Res.'}
/ Cancer Res. (2002)10.1083/jcb.200112023
/ J. Cell Biol. (2002)10.1091/mbc.e03-01-0860
/ Mol. Biol. Cell. (2003){'key': '2023072218191873900_BIB13', 'first-page': '4074', 'volume': '63', 'year': '2003', 'journal-title': 'Cancer Res.'}
/ Cancer Res. (2003)10.1016/S0960-894X(98)00495-8
/ Bioorg. Med. Chem. Lett. (1998)10.1091/mbc.e02-10-0653
/ Mol. Biol. Cell. (2003)10.1073/pnas.221430898
/ Proc. Natl. Acad. Sci. USA. (2001)10.1074/jbc.M206109200
/ J. Biol. Chem. (2002)10.1073/pnas.231623498
/ Proc. Natl. Acad. Sci. USA. (2002)10.1038/372467a0
/ Nature. (1994)10.1016/S0955-0674(00)00201-5
/ Curr. Opin. Cell Biol. (2001)10.1038/ncb884
/ Nat. Cell Biol. (2002)10.1074/jbc.270.37.21429
/ J. Biol. Chem. (1995)10.1093/emboj/16.8.1921
/ EMBO J. (1997)10.1038/sj.onc.1204177
/ Oncogene. (2001){'key': '2023072218191873900_BIB25', 'first-page': '1042', 'volume': '54', 'year': '1994', 'journal-title': 'Cancer Res.'}
/ Cancer Res. (1994)10.1038/38664
/ Nature. (1997)10.1074/jbc.273.25.15605
/ J. Biol. Chem. (1998)10.1126/science.7914033
/ Science. (1994)10.1074/jbc.M104383200
/ J. Biol. Chem. (2001)10.1006/cbir.2000.0557
/ Cell Biol. Internat. (2000)10.1667/0033-7587(2002)157[0026:CEGRIG]2.0.CO;2
/ Radiat. Res. (2002){'key': '2023072218191873900_BIB32', 'first-page': '210', 'volume': '1', 'year': '2002', 'journal-title': 'Cell Cycle.'}
/ Cell Cycle. (2002)10.1016/S1470-2045(02)00715-5
/ Lancet Oncol. (2002)10.1038/386732a0
/ Nature. (1997){'key': '2023072218191873900_BIB35', 'volume': 'In press', 'year': '2004', 'journal-title': 'Methods in Enzymology'}
/ Methods in Enzymology (2004)10.1152/physrev.2001.81.2.807
/ Physiol. Rev. (2001)10.1021/bi981591x
/ Biochemistry. (1998)10.1083/jcb.200401139
/ J. Cell Biol. (2004)10.1016/S0960-9822(02)00833-3
/ Curr. Biol. (2002)10.1016/S0960-9822(02)01226-5
/ Curr. Biol. (2002)10.1038/sj.onc.1207446
/ Oncogene. (2004)10.1016/S0006-2952(98)00082-3
/ Biochem. Pharmacol. (1998)10.1038/35050676
/ Nat. Cell Biol. (2001)10.1091/mbc.11.6.2069
/ Mol. Biol. Cell. (2000)10.1083/jcb.142.4.1013
/ J. Cell Biol. (1998)10.1016/S0960-9822(00)00678-3
/ Curr. Biol. (2000)10.1074/jbc.273.10.5858
/ J. Biol. Chem. (1998)10.1083/jcb.146.5.905
/ J. Cell Biol. (1999)10.1038/35019108
/ Nature. (2000)10.1126/science.280.5363.599
/ Science. (1998)10.1083/jcb.200202053
/ J. Cell Biol. (2002)10.1016/S0753-3322(98)80014-0
/ Biomed. Pharmacother. (1998)10.1038/sj.onc.1204126
/ Oncogene. (2001)10.1002/em.10072
/ Environ. Mol. Mutagen. (2002)10.1182/blood-2002-08-2617
/ Blood. (2003)10.1128/MCB.22.4.1049-1059.2002
/ Mol. Cell. Biol. (2002)10.1074/jbc.275.14.10342
/ J. Biol. Chem. (2000)
Dates
Type | When |
---|---|
Created | 21 years ago (Aug. 9, 2004, 8:13 p.m.) |
Deposited | 2 years, 1 month ago (July 22, 2023, 2:20 p.m.) |
Indexed | 10 months, 2 weeks ago (Oct. 5, 2024, 8:31 p.m.) |
Issued | 21 years ago (Aug. 9, 2004) |
Published | 21 years ago (Aug. 9, 2004) |
Published Online | 21 years ago (Aug. 9, 2004) |
Published Print | 21 years ago (Aug. 16, 2004) |
@article{Mikhailov_2004, title={Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway}, volume={166}, ISSN={0021-9525}, url={http://dx.doi.org/10.1083/jcb.200405167}, DOI={10.1083/jcb.200405167}, number={4}, journal={The Journal of Cell Biology}, publisher={Rockefeller University Press}, author={Mikhailov, Alexei and Shinohara, Mio and Rieder, Conly L.}, year={2004}, month=aug, pages={517–526} }